Table 6 Individual characteristics of nine critically ill septic patients with atorvastatin plasma concentrations assessment during treatment continuation
Patient | Age | Diagnosis | SAPS II | ICU survivor | CA | MV | Feeding | Cytochrome P450 3A4 inhibitors |
|---|---|---|---|---|---|---|---|---|
1 | 89 | Undocumented sepsis | 46 | Yes | Yes | No | Oral | No |
2 | 64 | Surgical site infection | 40 | Yes | Yes | Yes | OGT | No |
3 | 77 | Pneumonia | 44 | Yes | No | No | Oral | No |
4 | 74 | Pneumonia | 56 | No | Yes | Yes | OGT | Yes (amiodarone, midazolam, hydrocortisone) |
5 | 81 | Cholecystitis | 113 | No | Yes | Yes | OGT | Yes (midazolam, hydrocortisone) |
6 | 62 | Pneumonia | 54 | No | Yes | Yes | OGT | Yes (hydrocortisone) |
7 | 60 | Urosepsis | 35 | Yes | Yes | No | Oral | Yes (tacrolimus, hydrocortisone) |
8 | 56 | Urosepsis | 81 | Yes | Yes | Yes | OGT | Yes (midazolam) |
9 | 67 | Liver abscess | 67 | Yes | Yes | Yes | OGT | Yes (amiodarone, midazolam, hydrocortisone) |